In 3,000 medical staff administered intranasal IFN-α as a prophylactic during a COVID-19 outbreak, no new infections were seen during a 28-day observation period compared with 100 new infections in untreated staff at neighboring Wuhan hospitals (47). This evidence concerns the gene IFNA2 and COVID-19.